Purpose
Design
Subjects
Methods
Main Outcome Measures
Results
Conclusions
Financial Disclosure(s)
Keywords
Abbreviations and Acronyms:
BCVA (best-corrected visual acuity), BLR (blue light reflectance), CART (Classification and Regression Trees), CF (color fundus), EZ (ellipsoid zone), FAF (fundus autoflorescence), FLIO (fluorescence lifetime imaging ophthalmoscopy), MacTel (macular telangiectasia type 2), NHOR (natural history observation registry), NHOS (natural history observation study), OCTA (OCT angiography), SD-OCT (spectral domain-OCT), VA (visual acuity)1. | No obvious abnormality. early fluorescein shows minimal leakage and mild staining temporally |
2. | Graying of perifoveal retina, minimal or no telangiectatic vessels: early fluorescein shows outer capillary network temporally |
3. | Blunted & right-angle veins: fluorescein (stereo) shows unusual capillary dilation and permeability in outer retina |
4. | Pigmentation: often associated within the blunted tips of right-angle veins. |
5. | Subretinal neovascular: biomicroscopic and fluorescein evidence of neovascularization |
Methods
MacTel Project
NHOS (2005–2015)
NHOR
Fundus Reading Center at Moorfields Eye Hospital
Venkatesh R, Agrawal S, Reddy N.G, et al. Characteristics of retinal pigment clumps in Type 2 macular telangiectasia (MacTel), Eye (Lond), 2022. Accessed April 14, 2022. doi: 10.1038/s41433-022-02065-8. Online ahead of print. PMID: 35422496
Yasvoina M, Yang Q, Woods S.M, et al. Intraretinal pigmented cells in retinal degenerative disease, Br J Ophthalmol, 2022. Accessed March 17, 2022. doi: 10.1136/bjophthalmol-2021-320392. Online ahead of print.
Statistical Analyses
Reading Center Variables Evaluated in the CART Analyses





Results
The Classification of MacTel
Classification of Macular Telangiectasia Type 2 (MacTel Classification) (Following Diagnosis of MacTel Confirmed with OCT, Fluorescein Angiography, Fundus Autofluorescence, Blue-light Reflectance, or Color Fundus Photographs) | |
---|---|
Grade | Description of Each Grade |
0 | No EZ Break/No Pigmentation/No OCT HR |
1 | Noncentral EZ Break/No pigment/No OCT HR |
2 | Central EZ break/No pigment/No OCT HR |
3 | Noncentral pigment/No, non-central, or central EZ/No OCT HR |
4 | OCT HR/EZ break (either central or noncentral)/No pigment |
5 | Central pigment/no exudative neovascularization/EZ present or not gradable |
6 | Neovascularization (exudative) ± central pigment |
Follow-Up Analyses Using the Mac Tel Classification System
Discussion
Simple MacTel Classification | |
---|---|
Grade | Essential factor of Each Grade |
0 | No lesions |
1 | Noncentral ellipsoid zone (EZ) Break |
2 | Central EZ break |
3 | Noncentral pigment |
4 | OCT hyper-reflectivity |
5 | Central pigment |
6 | Neovascularization (exudative) |
Supplementary data
- Figs S1–S7
- Supplementary Materials
- Tables S1–S4
References
- Progression of vision loss in macular telangiectasia type 2.Invest Ophthalmol Vis Sci. 2015; 56: 3905-3912
- Macular telangiectasia type 2.Prog Retin Eye Res. 2013; 34: 49-77
- The National eye institute visual function questionnaire in the macular telangiectasia (MacTel) Project.Invest Ophthalmol Vis Sci. 2008; 49: 4340-4346
- Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia.Invest Ophthalmol Vis Sci. 2007; 48: 3788-3795
- Macular telangiectasia type 2: visual acuity, disease end grade, and the MacTel area: MacTel Project report number 8.Ophthalmology. 2020; 127: 1539-1548
- Binocular inhibition of reading in macular telangiectasia type 2.Invest Ophthalmol Vis Sci. 2019; 60: 3835-3841
- Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study.Ophthalmology. 1993; 100: 1536-1546
- Abnormal retinal reflectivity to short-wavelength light in type 2 idiopathic macular telangiectasia.Retina. 2018; 38 Suppl 1: S79-S88
- Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia.Invest Ophthalmol Vis Sci. 2008; 49: 1172-1177
- Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2.Ophthalmic Epidemiol. 2010; 17: 66-73
- "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia.Invest Ophthalmol Vis Sci. 2012; 53: 6145-6152
- OCT angiography and ellipsoid zone mapping of macular telangiectasia type 2 from the AVATAR study.Invest Ophthalmol Vis Sci. 2017; 58: 3683-3689
- OCT of outer retinal hyperreflectivity, neovascularization, and pigment in macular telangiectasia type 2.Ophthalmol Retina. 2021; 5: 562-570
- Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2.Ophthalmology. 2010; 117: 2162-2168
- Hyperreflectivity on optical coherence tomography in macular telangiectasia type 2.Retina. 2021; 41: 1428-1437
- Characterizing retinal-choroidal anastomosis in macular telangiectasia type 2 with optical coherence tomography angiography.Retina. 2020; 40: 92-98
- Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2.Br J Ophthalmol. 2021; 105: 573-576
- Very early disease manifestations of macular telangiectasia type 2.Retina. 2016; 36: 524-534
- Fundus autofluorescence imaging in macular telangiectasia type 2: MacTel study report number 9.Am J Ophthalmol. 2021; 228: 27-34
- Right-angled vessels in macular telangiectasia type 2.Br J Ophthalmol. 2021; 105: 1289-1296
- Characteristics of pigmented lesions in type 2 idiopathic macular telangiectasia.Retina. 2018; 38 Suppl 1: S43-S50
Venkatesh R, Agrawal S, Reddy N.G, et al. Characteristics of retinal pigment clumps in Type 2 macular telangiectasia (MacTel), Eye (Lond), 2022. Accessed April 14, 2022. doi: 10.1038/s41433-022-02065-8. Online ahead of print. PMID: 35422496
Yasvoina M, Yang Q, Woods S.M, et al. Intraretinal pigmented cells in retinal degenerative disease, Br J Ophthalmol, 2022. Accessed March 17, 2022. doi: 10.1136/bjophthalmol-2021-320392. Online ahead of print.
- Classification and regression trees.Wadsworth International Group, Belmont, Calif.1984
- An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group.Surv Ophthalmol. 1995; 39: 367-374
- Correlation of clinical and structural progression with visual acuity loss in macular telangiectasia type 2: MacTel Project report No. 6-The MacTel research group.Retina. 2018; 38 Suppl 1: S8-S13
- Retinal cavitations in macular telangiectasia type 2 (MacTel): longitudinal structure-function correlations.Br J Ophthalmol. 2021; 105: 109-112
- Deep learning-based classification and segmentation of retinal cavitations on optical coherence tomography images of macular telangiectasia type 2.Br J Ophthalmol. 2022; 106: 396-402
- Genesis of retinal-choroidal anastomosis in macular telangiectasia type 2: a longitudinal analysis.Retina. 2021; 41: 464-470
- Spectral domain OCT features in type 2 macular telangiectasia (type 2 MacTel): its relevance with clinical staging and visual acuity.Int J Retina Vitreous. 2022; 8: 26
- Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial.Ophthalmology. 2019; 126: 540-549
- Fluorescence lifetime imaging ophthalmoscopy (FLIO) patterns in clinically unaffected children of macular telangiectasia type 2 (MACTEL) patients.Retina. 2020; 40: 695-704
- Fluorescence lifetime patterns in macular telangiectasia type 2.Retina. 2020; 40: 99-108
- Longitudinal fluorescence lifetime imaging ophthalmoscopy analysis in patients with macular telangiectasia type 2 (MacTel).Retina. 2021; 41: 1416-1427
Article info
Publication history
Footnotes
Dr Emily Y. Chew, the Editor-in-Chief of this journal, was recused from the peer-review process of this article and had no access to information regarding its peer-review.
Supplemental material available at www.ophthalmologyscience.org.
Disclosures.
All authors have completed and submitted the ICMJE disclosures form.
The authors made the following disclosures: T.P.: Speakers’ fee and advisory board fee – Bayer, Novartis, Roche, Alimera, Apellis, OPTOS, Heidelberg (not relevant to the current work).
D.P.: Consultant – Allergan, Apellis, Bayer, Heidelberg Engineering, Novartis, Roche; Study support – Allergan, Apellis, Bayer, Heidelberg Engineering, Novartis, Roche.
C.E.: Fees for professional consultation – Heidelberg Engineering.
G.J.J.: Consultant – Neurotech.
K.B.: Grant support – Bayer, Novartis, Apellis, Roche; Consultant – Novartis, Bayer, Roche, Google; Speaker – Novartis, Bayer, Roche, Apellis, Alimera, Allergan, Heidelberg Engineering.
F.G.H.: Research grants and consulting fees – Heidelberg Engineering, Zeiss.
This research was supported by the Intramural Research Program of the National Eye Institute, National Institutes of Health, Bethesda, MD, USA, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Oxford, United Kingdom, and the Lowy Medical Research institute.
HUMAN SUBJECTS: Human subjects were included in this study. Each participating clinical site obtained approval from its institutional review board or independent ethics committee for the protocol. All research adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent.
No animal subjects were used in this study.
Author Contributions:
Research design: Chew, Peto, Clemons, Sallo, Bird, Friedlander
Data acquisition: Chew, Peto, Clemons, Sallo, Pauleikhoff, Leung, Jaffe, Heeren, Egan, Issa, Balaskas, Holz, Gaudric
Data analysis: Chew, Peto, Clemons, Sallo, Pauleikhoff, Leung, Jaffe, Heeren, Egan, Issa, Balaskas, Holz, Gaudric, Bird, Friedlander
Obtained funding: N/A
Manuscript preparation: Chew, Peto, Clemons, Sallo, Pauleikhoff, Leung, Jaffe, Heeren, Egan, Issa, Balaskas, Holz, Gaudric, Bird, Friedlander.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy